Morphogen-IX

The company's core focus is the development of therapies for pulmonary arterial hypertension, a rare and life-threatening condition characterized by the narrowing of blood vessels in the lungs, which leads to heart failure. Morphogen-IX's business model is centered on the research and development of a disease-modifying drug, targeting the fundamental causes of PAH rather than merely alleviating symptoms. The primary client base for its eventual product consists of patients suffering from this debilitating disease. The company's main therapeutic candidate, MGX292, is a protein-engineered variant of Bone Morphogenetic Protein 9 (BMP9). This engineered protein is designed to restore the protective function of the native BMP9 protein for lung blood vessels, a function that is often reduced in patients due to genetic causes, without inducing the bone-forming properties of the natural protein.

Significant milestones for Morphogen-IX include securing £1.5 million in seed funding in 2016, led by Index Ventures, Cambridge Innovation Capital, and Cambridge Enterprise. This was followed by a substantial £18.4 million Series B financing round in December 2018, led by Medicxi, to advance MGX292 through preclinical development and into clinical trials. In a strategic move in February 2021, Morphogen-IX was acquired by Centessa Pharmaceuticals through a share exchange, becoming one of 10 biotech companies merged to form the new entity. This acquisition provided the financial backing and scaled R&D model necessary to further the development of its promising pipeline.